SPL Medical announces the first time mentioning of its novel contrast agent Ferrotran® (Ferumoxtran) in the German S3-guidelines for Prostate Cancer

Novel imaging agent mentioned in German S3-Guidelines Prostate Cancer

Nijmegen, Netherlands, 27.05.2021 – SPL Medical announced today that the new issue of the German S3-guidelines for prostate cancer, released this month by the Guideline Program Oncology of the German Cancer Society, Deutsche Krebshilfe and AWMF, for the first time is mentioning Ferrotran® (Ferumoxtran) on page 25 of the Guideline Report document.

Read the full text >>.

Head-to-head comparison of 68Ga-prostate-specific membrane antigen PET/CT and ferumoxtran-10 enhanced MRI for the diagnosis of lymph node metastases in prostate cancer patients

The goal of this first study comparing Nano-MRI (MRI with a ferumoxtran-10 contrast agent) and 68Ga PSMA- PET/CT was to investigate a potential complementary role for these novel imaging modalities in identifying suspect lymph nodes in prostate cancer patients. Nano-MRI in a comparison with 68Ga-PSMA- PET/CT identified significantly more suspected lymph nodes; at the same, nano-MRI appeared to be superior in detecting smaller suspicious LNs. Both methods seem to be complementary in their potential clinical use.

Read the full text >>.